Relaxin
Relaxin (RLX)
A peptide hormone with potent anti-fibrotic, vasodilatory, and connective tissue remodeling properties. Used clinically for acute heart failure and studied for fibrotic diseases.
Mechanism of Action
Relaxin binds to RXFP1 receptors, activating cAMP and nitric oxide pathways. It inhibits TGF-beta-mediated fibrosis, promotes collagen degradation, and has vasodilatory effects.
Health Claims & Evidence
Potent anti-fibrotic effects
Reduces cardiac fibrosis and improves heart failure
Improves connective tissue flexibility
Short-Term Effects
Improved cardiac function, reduced fibrosis markers.
Long-Term Effects
Potential for sustained anti-fibrotic benefits.
Side Effects
Hypotension, headache, potential renal effects.
Contraindications
Use with caution in hypotension.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Serelaxin in acute heart failure
Teerlink et al. · Lancet · 2013
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Relaxin and related peptides, and prepare an educational research summary.
Explore Research